
    
      This was a 3 arm randomized, open-label, comparative, multi-center study in de novo kidney
      transplant recipients at 60 centers in the U.S., Canada and Brazil.

      The study consisted of a 1-year post-transplant efficacy and safety study with a clinical
      continuation phase of a minimum of 2 years or until commercial availability of tacrolimus
      modified release, unless the Data Safety Monitoring Board or sponsor specified otherwise.
    
  